Zhang W, et al. - Among adult patients presenting with gastrointestinal symptoms in Canada, researchers evaluated the cost-effectiveness of adding a fecal calprotectin (FC) test vs standard practice (blood test) in primary care. Study participants included a hypothetical cohort of adult subjects presenting with gastrointestinal symptoms in the primary care setting. According to findings, FC testing is expected to cost more ($C295.1 vs $C273.9) than standard practice but yield slightly higher quality-adjusted life years (QALY; 0.751 vs 0.750). Incremental cost-effectiveness ratio (ICER) of FC test was $C20,323 per QALY. Using the primary care FC test reduced inflammatory bowel disease (IBD) diagnosis time by 40.0 days vs blood testing alone. Based on this analysis of short-term results, using FC at the 100 µg/g cut-off in primary care for IBD diagnosis can be a cost-effective strategy and can accelerate the diagnosis of IBD in adults with gastrointestinal symptoms.